DR. KRISTI JO MCINTYRE MD NPI 1912949033

NPI Information

  • NPI: 1912949033
  • Provider Name: DR. KRISTI JO MCINTYRE, MD
  • Classification: Internal Medicine - 207RX0202X
  • Specialization: Medical Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 8220 WALNUT HILL LN
    PROFESSIONAL BLDG II, SUITE 700
    DALLAS, TX
    ZIP 75231
  • Phone: (214) 739-4175

Map and Directions

Get Directions

NPI Details

DR. Kristi Jo Mcintyre, MD is a medical oncology internal medicine in Dallas, TX with 43 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Kristi Jo Mcintyre, MD NPI is 1912949033. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: TULANE UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1982

The provider's business location address is:

8220 WALNUT HILL LN
PROFESSIONAL BLDG II, SUITE 700
DALLAS, TX
ZIP 75231-427
Phone: (214) 739-4175
Fax: (214) 987-4161

The NPI 1912949033 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, iron sucrose, 1 mg (HCPCS:J1756)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
  • Blood test, comprehensive group of blood chemicals (HCPCS:80053)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
  • Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Iron level (HCPCS:83540)
  • Ferritin (blood protein) level (HCPCS:82728)
  • Iron binding capacity (HCPCS:83550)
  • Lactate dehydrogenase (enzyme) level (HCPCS:83615)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Unclassified drugs (HCPCS:J3490)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Ultrasound of heart with color-depicted blood flow, rate, direction and valve function (HCPCS:93306)
  • Injection of drug or substance into vein (HCPCS:96374)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Heart muscle strain imaging (HCPCS:93356)
  • Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
  • Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 6/12/2006 and was last updated on 2/22/2008.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RX0202XInternal MedicineMedical OncologyH9380TEXASYes

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.

No. Other Provider Identifier Other Provider Identifier Type Other Provider Identifier State Other Provider Identifier Issuer
1E40753MEDICARE UPIN
28R1501OTHERTEXASBLUE CROSS OF TX
38B5700MEDICARE PINTEXAS
488248KMEDICARE PINTEXAS

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 3/30/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.